Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary

Alvar Agustí a,⁎,1, Bartolome R. Celi b,1, Gerard J. Criner c, David Halpin d, Antonio Anzueto e, Peter Barnes f, Jean Bourbeau g, MeiLan K. Han h, Fernando J. Martinez i, Maria Montes de Oca j, Kevin Mortimer k,⁎,†, Alberto Papi n, Ian Pavord o, Nicolas Roche p, Sundeep Salvi q, Don D. Sin r, Dave Singh s, Robert Stockley t, M. Victorina López Varela u, Jadwiga A. Wedzicha f, Claus F. Vogelmeier v

a University of Barcelona, Hospital Clinic, IDIBAPS and CIBERES, Spain
b Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
c Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA
d University of Exeter Medical School, College of Medicine and Health, University of Exeter, Exeter, Devon, UK
e South Texas Veterans Health Care System, University of Texas, Health San Antonio, Texas, USA
f National Heart & Lung Institute, Imperial College London, United Kingdom
g McGill University Health Centre, McGill University, Montreal, Canada
h University of Michigan, Ann Arbor, MI, USA
i Weil Cornell Medical Center/New York-Presbyterian Hospital, New York, NY, USA
j Hospital Universitario de Caracas, Universidad Central de Venezuela, Centro Médico de Caracas, Caracas, Venezuela
k Liverpool University Hospitals NHS Foundation Trust, UK
l National Heart and Lung Institute, Imperial College London, UK
m School of Clinical Medicine, College of Health Sciences, University of KwaZulu-Natal, South Africa
n University of Ferrara, Ferrara, Italy
o Respiratory Medicine Unit and Oxford Respiratory NIHR Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, UK
p Pneumologie, Hôpital Cochin AP-HP, Centre, Université Paris, France
q Pulmonary Research and Education (PURE) Foundation, Pune, India
r St Paul’s Hospital, University of British Columbia, Vancouver, Canada
s University of Manchester, Manchester, UK
t University Hospital, Birmingham, UK
u Universidad de la República, Hospital Maciel, Montevideo, Uruguay
v Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University, German Center for Lung Research (DZL), Marburg, Germany

ARTICLE INFO

Article history:
Received 6 February 2023
Accepted 6 February 2023
Available online 1 March 2023

Introduction

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) has published the complete 2023 GOLD report, which can be freely downloaded from its web page (www.goldcopd.org) together with a “pocket guide” and “teaching slide set”. It contains important changes compared to earlier versions, and incorporates 387 new references. Here, we present an executive summary of this GOLD 2023 report that summarizes aspects that (a) are relevant from a clinician’s perspective and (b) updates evidence published since the prior executive summary in 2017.

New Definition of COPD

The definition of a disease should only include the characteristics that distinguishes it from other diseases. Accordingly, GOLD...
2023 proposes a new definition of COPD that, at variance with previous documents, focuses exclusively on these characteristics, separately from its epidemiology, causes, risk factors and diagnostic criteria that are discussed on their own.

GOLD 2023 defines COPD as a heterogeneous lung condition characterized by chronic respiratory symptoms (dyspnea, cough, expectoration and/or exacerbations) due to abnormalities of the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often progressive, airflow obstruction.

**Pathogenesis: Causes and Risk Factors**

COPD results from dynamic, cumulative and repeated gene (G) – environment (E) interactions over the lifetime (T) that damage the lungs and/or alter their normal development/aging processes (GETomics). Environmental Risk Factors

Cigarette smoking is a key environmental risk factor for COPD. Cigarette smokers have a higher prevalence of respiratory symptoms and lung function abnormalities, a greater annual rate FEV₁ decline and a greater COPD mortality rate than non-smokers; yet fewer than 50% of heavy smokers develop COPD. Passive exposure to cigarette smoke, other types of tobacco smoke (e.g., pipe, cigar, water pipe), and marijuana are also risk factors for COPD. Smoking during pregnancy poses a risk for the fetus, by altering lung growth and development in utero, and possibly priming the immune system for abnormal/enhanced responses in the future.

In low- and middle-income countries (LMICs), COPD in non-smokers may be responsible for up to 60–70% of cases. Because the LMICs contribute to over 85% of all COPD cases, non-smoking risk factors account for over 50% of the global burden of COPD. Wood, animal dung, crop residues, and coal (i.e., biomass), typically burned in poorly functioning stoves, may lead to very high levels of household air pollution, which is associated with increased COPD risk, although the extent to which household air pollution versus other poverty-related exposures explain the association is unclear. Compared to COPD in smokers, COPD nonsmokers is more common in females, of younger age, and exhibit similar (or milder) respiratory symptoms and quality of life impairment. They have similar spirometric indices but greater small airways obstruction, less emphysema and lesser rate of lung function decline. Finally, they show lower neutrophil count, higher eosinophil numbers in the sputum and a similar defect in macrophage phagocytosis of pathogenic bacteria. Research is needed to understand how interventions aimed at decreasing household air pollution can reduce the risk of COPD as well as what is the most appropriate pharmacotherapy for this type of COPD.

Occupational exposures, including organic and inorganic dusts, chemical agents, and fumes, are an under-appreciated environmental risk factor for COPD. The U.S. National Health and Nutrition Examination Survey III estimated the fraction of COPD attributable to workplace exposures was 19.2% overall, and 31.1% among never-smokers.

Air pollution, which typically consists of particulate matter (PM), ozone, oxides of nitrogen or sulfur, heavy metals, and other greenhouse gases, is a major worldwide cause of COPD, responsible for −50% of the attributable risk for COPD in LMICs. The risk of air pollution to individuals is dose-dependent with no apparent “safe” threshold. Even in countries with relatively low ambient air pollution levels, chronic exposure to PM < 2.5 µm and nitrogen oxides significantly impairs lung growth in children, accelerates lung function decline in adults and increases the risk for COPD, especially among those with additional risk factors.

Also increases the risk of COPD exacerbations, hospitalizations, and mortality.

**Genetic Risk Factors**

The most relevant genetic risk factor for COPD identified are mutations in SERPINA1, leading to α-1 antitrypsin deficiency, a major circulating inhibitor of serine proteases. The PiZZ genotype affects 0.12% of COPD patients, and its prevalence ranges from 1/408 in Northern Europe to 1/1274 in Eastern Europe. There is no increased COPD risk in heterozygotes (MZ and SZ) in the absence of smoking.

Other genetic variants have also been associated with reduced lung function and risk of COPD, their individual effect size is small although their co-occurrence may increase disease susceptibility.

**Lung Function Trajectories: Lung Development and Ageing**

At birth, the lungs are not fully developed. They grow and mature until about 20–25 years of age (earlier in females), when lung function reaches its peak. This is followed by a relatively short plateau and a final phase of mild lung function decline due to physiological lung aging. This normal lung function trajectory can be altered by processes occurring during gestation, birth, childhood, and adolescence that affect lung growth (hence, peak lung function) and/or processes shortening the plateau phase and/or accelerating the aging phase. Indeed, the general population there is a range of lung function trajectories through the lifetime. Trajectories below the normal range are associated with a higher prevalence and earlier incidence of multi-morbidity and premature death, whereas those above the normal range are associated with healthier aging, fewer cardiovascular and respiratory events, as well as a survival benefit.

Factors in early life termed “childhood disadvantage factors”, including prematurity, low birth weight, maternal smoking during pregnancy, repeated respiratory infections and poor nutrition, among others, are key determinants of peak lung function attained in early adulthood. Reduced peak lung function in early adulthood increases the risk of COPD later in life. In fact, approximately 50% of patients develop COPD due to accelerated decline in FEV₁ over time while the other 50% develop it due to abnormal lung growth and development (with normal lung function decline over time).

**Sex**

The prevalence of COPD in developed countries is now almost equal in males and females. Women report more dyspnea, worse health status scores and have a higher incidence of exacerbations compared with men at similar severity of airflow limitation.

**Socioeconomic Status**

Poverty and lower socioeconomic status are consistently associated with airflow obstruction and increased risk of COPD. It is likely that this reflects exposures to household and outdoor air pollutants, crowding, poor nutrition, infections, or other factors related to low socioeconomic status.

**Asthma**

Many different studies have reported that asthma and atopy in infancy may be a significant risk factor for COPD in adulthood. However, it is important to remember that abnormal lung development in childhood and adolescence can cause asthma-like symptoms. Given that poor lung development is associated with
COPD in adulthood (see above), some of these infants and adolescents may have been mislabeled as “asthma”.

Infections

Severe respiratory infections in childhood have been associated with reduced lung function and increased respiratory symptoms in adulthood.\(^{47,48}\) In adults, chronic bronchial infection, particularly with *Pseudomonas aeruginosa*, is associated with accelerated FEV\(_1\) decline.\(^{26}\) In many parts of the world, tuberculosis\(^{51}\) and HIV infection\(^{52}\) are also important risk factors for COPD.

Diagnosis: Forced Spirometry

A diagnosis of COPD should be considered in any patient who complains of dyspnea, chronic cough or sputum production, a history of recurrent lower respiratory tract infections and/or a history of exposure to risk factors for the disease (see above) but forced vital capacity maneuver during spirometry showing the presence of a post-bronchodilator FEV\(_1\)/FVC <0.7 is needed to establish the diagnosis of COPD. The FEV\(_1\) also serves to determine the severity of airflow obstruction (GOLD grades 1, 2, 3, or 4 mild, moderate, severe, and very severe). Yet, several important aspects related to forced spirometry need to be considered here.

First, airflow obstruction that is not fully reversible is not specific for COPD. For instance, it may also be found in patients with asthma and other diseases, so the clinical context and risk factors (see above) must also be considered when establishing a diagnosis of COPD.

Second, if the post-bronchodilator FEV\(_1\)/FVC ratio is between 0.60 and 0.80 on a single *spirometric measurement*, this should be confirmed by repeat spirometry on a separate occasion, as in some cases the ratio may change as a result of biological variation when measured at a later interval.\(^{53,54}\) When the initial post-bronchodilator FEV\(_1\)/FVC ratio is <0.6, it is very unlikely to rise spontaneously above 0.7.\(^{53}\)

Third, there is a long-standing debate on whether it is better to use a fixed FEV\(_1\)/FVC ratio <0.7 or the *lower limit of normal* (LLN) for the diagnosis of COPD. GOLD favors the use of the former because it is simple and independent of reference values, since it relates to variables measured in the same individual and has been used in all the clinical trials that form the evidence base on which treatment recommendations are drawn. GOLD 2023 acknowledges that use of a fixed FEV\(_1\)/FVC ratio <0.7 to define airflow obstruction may underdiagnose young adults and over-diagnose the elderly,\(^{53,56}\) especially in mild disease, compared to using the LLN values of FEV\(_1\)/FVC. LLN values are based on the normal distribution and classify the bottom 5% of the healthy population as abnormal. Thus, LLN values are highly dependent on the choice of reference equations as well as race/ethnicity, and there are no longitudinal studies available validating the use of the LLN. Further, using the fixed ratio is not inferior to LLN regarding prognosis.\(^{57}\) Finally, the risk of misdiagnosis and over-treatment of individual patients using the fixed ratio as a diagnostic criterion is limited, as spirometry is only one biologic measurement to establish the clinical diagnosis of COPD in the appropriate clinical context (symptoms and risk factors). Diagnostic simplicity and consistency are crucial for the busy clinician.

Fourth, while *post-bronchodilator spirometry* is required for the diagnosis and assessment of COPD, assessing the degree of reversibility of airflow obstruction to inform therapeutic decisions is no longer recommended.\(^{58}\) The degree of reversibility in a single patient varies over time and has not been shown to differentiate COPD from asthma (except when airflow limitation disappears following bronchodilators, which is incompatible with COPD), or to predict the response to long-term treatment with bronchodilators or corticosteroids.\(^{59}\) Accordingly, it is not necessary nor advised to stop inhaled medication before obtaining spirometry measurements during follow-up of patients.

Finally, the role of *screening spirometry* in the general population for the diagnosis of COPD is also controversial. In asymptomatic individuals without any significant exposure to tobacco or other risk factors, screening spirometry is probably not indicated. By contrast, in those with symptoms and/or risk factors (e.g., >20 pack-years of smoking, recurrent chest infections, prematurity or other significant early life events), the diagnostic yield for COPD is relatively high and spirometry should be considered as a method for case finding.\(^1\)

Terminology

As mentioned above, it is now well established that a range of lung function trajectories exist through life\(^{58,60}\) and that COPD can develop by both abnormal lung development and/or accelerated lung aging.\(^{42}\) This has generated some terminology confusion, so GOLD proposes use of the following terminology\(^7:\)

*Early COPD*

The word “early” means “near the beginning of a process”. Because COPD can start early in life and take a long time to manifest clinically, identifying “early” COPD is difficult. Further, a biological “early” related to the initial mechanisms that eventually lead to COPD should be differentiated from a clinical “early”, which reflects the initial perception of symptoms, functional limitation and/or structural abnormalities noted. Thus, GOLD proposes to use the term “early COPD” only to discuss the “biological” first steps of the disease in an experimental setting.

*Mild COPD*

Some studies have used “mild” airflow obstruction as a surrogate for “early” disease.\(^{61}\) This assumption is incorrect because not all patients started their journey from a normal peak lung function in early adulthood, so some of them may never suffer “mild” disease in terms of “severity” of airflow obstruction.\(^{28}\) Further, “mild” disease can occur at any age and may progress, or not, over time.\(^{60}\) Accordingly, GOLD proposes that “mild” should be used only to describe the severity of airflow obstruction measured spirometrically.

*Young COPD*

The term “young COPD” is seemingly straightforward because it directly relates to the “chronological” age of the patient.\(^{52}\) Given that lung function peaks at around 20 years\(^3\) and starts to decline around 40–50 years, GOLD proposes to operationally consider “young COPD” in patients aged 20–50 years\(^53\) whether from having never achieved normal peak lung function in early adulthood and/or from shorter plateau and/or early lung function decline.\(^{64,65}\) COPD in “young” people may be associated with significant structural and functional lung abnormalities with substantial impact on health.\(^{65,66}\) A family history of respiratory diseases and/or early-life events (including hospitalizations before the age of 5 years) is reported by a significant proportion of young patients with COPD.\(^{65}\)

*Pre-COPD*

This term has been proposed to identify individuals of any age, with respiratory symptoms and/or other detectable structural (e.g., emphysema) and/or functional abnormalities (e.g., hyperinflation, reduced lung diffusing capacity, or rapid FEV\(_1\) decline), in
the absence of airflow obstruction on post-bronchodilator spirometry (i.e., FEV1/FVC > 0.7). These patients may (or not) develop persistent airflow obstruction (i.e., COPD) over time. Yet, people with pre-COPD so defined should already be considered “patients” because they suffer symptoms and/or have functional and/or structural abnormalities. Currently, there is no evidence on what the best treatment is for these patients. There urgently is a need for RCTs, both in patients with ‘Pre-COPD’, and in young people with COPD. Research in this area would benefit from pediatric-to-adulthood cohorts and more active case-finding strategies.

**PRISm**

This term has been proposed to describe individuals with FEV1/FVC ≥0.7 and FEV1 <80% of reference after bronchodilation. Its prevalence ranges from 7.1% to 20.3%, is particularly high in current and former smokers, and is associated with increased all-cause mortality. PRISm can transition to normal, obstructive or restrictive spirometry over time. Despite an increasing body of literature on PRISm, significant knowledge gaps remain in relation to its pathogenesis and treatment.

**Taxonomy**

Based on the different causes (or etiotypes) that can contribute to COPD (see above) GOLD 2023 proposes a new taxonomic classification of COPD (Fig. 1) that reflects two recent proposals. It aims to raise awareness about non-smoking related COPD and to stimulate research on the mechanisms and corresponding diagnostic, preventive or therapeutic approaches for these other etiotypes of COPD which are highly prevalent around the globe.

**Clinical Presentation**

Patients with COPD may complain of dyspnea, wheezing, chest tightness, fatigue, activity limitation and/or cough with or without sputum production and may experience acute respiratory events characterized by acute worsening of respiratory symptoms called exacerbations that require specific preventive and therapeutic measures. Patients with COPD frequently harbor other comorbid diseases (multimorbidity) that influence their clinical condition and prognosis, independently of the severity of airflow obstruction due to COPD, and require specific treatment (see below).

**Assessment**

Once the diagnosis of COPD has been confirmed by spirometry, the goals of the initial assessment of COPD to guide therapy are to determine: (1) the severity of airflow limitation (GOLD spirometric grades); (2) the nature and magnitude of current symptoms; (3) the previous history of moderate and severe exacerbations (the best estimate of the risk of future exacerbations); and (4) the presence and type of multimorbidity.

**Combined Initial COPD Assessment: From ABCD to ABE**

GOLD 2023 modifies the ABCD assessment tool of previous editions to recognize the clinical impact of exacerbations independently of the level of symptoms of the patient (Fig. 2). The thresholds proposed for symptoms (X axis) and history of exacerbations in the previous year (Y axis) are unchanged from previous GOLD documents, so the A and B groups remain unchanged, while the former C and D groups are now merged into a single group termed “E” (for “Exacerbations”). This has implications for the initial pharmacological treatment recommendations, as discussed below. The practical value of this proposal needs to be validated by appropriate clinical research.

**Imaging**

A chest X-ray cannot confirm a diagnosis of COPD. However, radiological changes associated with COPD may include signs of lung hyperinflation (flattened diaphragm and increased retrosternal air space), lung hyperlucency, and rapid tapering of the vascular
Choice and Appropriate Use of Inhaler Devices

Because inhaled therapy is the cornerstone of COPD treatment, the appropriate use of these devices is crucial to optimize the benefit-risk ratio of any inhaled therapy. Achieving this goal requires educating and training the providers and the patients in the correct use of the device. Regular assessment at follow-up is necessary to maintain their effective use. Details on the choice of device can be found in the complete GOLD 2023 document and include availability, patient preferences and ability to perform the correct inhalation maneuver.84

Initial Pharmacological Treatment

Fig. 3 shows the 2023 GOLD recommendation for initiation of pharmacological therapy. The treatment of patients in Group A has not changed. In contrast, for patients in Group B, a dual long-acting bronchodilator combination (B2 adrenergic (LABA) + anti-muscarinic (LAMA) bronchodilators) is now recommended since dual therapy is more effective than monotherapy with similar side-effects.85–87 For patients in Group E, LAMA + LABA is also the recommended initial therapy, except for those patients with blood eosinophils ≥300 cells/μL, in whom starting triple therapy (LABA + LAMA + ICS) can be considered. This is a practical recommendation; direct evidence is not available to guide therapy in naïve individuals. The role of the blood eosinophil count for the reduction of the exacerbation risk with ICS is explicitly discussed below. The use of LABA + ICS in COPD is no longer encouraged. If there is an indication for an ICS, then LABA + LAMA + ICS has been shown to be superior to LABA + ICS and is therefore the preferred choice.88,89 If patients with COPD have concomitant asthma, they should be treated as if they have asthma.90

Pharmacological Treatment

Pharmacological therapy must be always associated with non-pharmacological measures described later, starting with smoking cessation when needed.
Fig. 3. Initial pharmacological treatment. Exacerbation history refers to exacerbations suffered the previous year. *: single inhaler therapy may be more convenient and effective than multiple inhalers. mMRC: modified Medical Research Dyspnea Questionnaire. CAT: COPD Assessment Test. LAMA: long-acting anti-muscarinic antagonist; LABA: long-acting β2 receptor agonist; ICS: inhaled corticosteroid; eos: eosinophils.
Reproduced with permission from www.goldcopd.org.

Follow-up Pharmacological Treatment

Following initial therapy, patients should be reassessed guided by the principles of first review and assess, then adjust if needed.

GOLD 2023 continues to recommend that follow-up treatment be based on two key treatable traits (TTs):001: dyspnea and occurrence of exacerbations (Fig. 4). TTs can be identified based on clinical recognition (phenotypes) and/or on deep understanding of critical causal pathways (endotypes) through validated biomarkers (e.g., circulating eosinophils to guide treatment with inhaled corticosteroids (ICS) in COPD patients with evidence of T2 inflammation).01 Importantly, TTs can co-exist in the same patient02 and change with time (spontaneously or because of treatment). GOLD 2023 recommendations for follow-up treatment for both TTs (dyspnea and exacerbations) broadly follow previous recommendations but no longer include LABA + ICS for the reasons stated above (see initial treatment).

For patients with persistent dyspnea or exercise limitation on bronchodilator monotherapy, a step up to LABA + LAMA is recommended. If this does not improve symptoms clinicians should consider switching inhaler device or molecules, as well as investigating and treating other causes of dyspnea.

For patients continuing to have exacerbations (with or without dyspnea) on bronchodilator monotherapy, escalation to LABA + LAMA is recommended, except for patients with blood eosinophils ≥300 cells/µL who may be escalated to LABA + LAMA + ICS. For patients with persistent exacerbations on LABA + LAMA, escalation to LABA + LAMA + ICS is recommended if they have blood eosinophils ≥100 cells/µL. For patients continuing to exacerbate despite therapy with LABA + LAMA + ICS or those who have an eosinophil count of <100 cells/µL, the addition of roflumilast (particularly in patients with chronic bronchitis and an FEV₁ <50% predicted)03–05 or a macrolide (particularly in patients who are not current smokers) may be considered.06,07

Patients whose pharmacological treatment is modified should be closely monitored. Treatment escalation has not been systematically tested and trials of de-escalation are limited to withdrawing ICS.08 As indicated in Fig. 4, ICS de-escalation can be considered if pneumonia or other considerable side-effects. In case of blood eos ≥300 cells/µL, ICS de-escalation is more likely to be associated with development of exacerbations. Finally, if a patient with COPD and no features of asthma has already been treated – for whatever reason – with LABA + ICS and is well controlled in terms of symptoms and exacerbations, then LABA + ICS could be continued. However, if they remain dyspneic switching to LABA + LAMA should be considered, and if they have further exacerbations, treatment should be escalated to LABA + LAMA + ICS.

Other Therapeutic Considerations

The Eosinophil as a Useful Clinical Biomarker

As in previous GOLD reports, the main factors to consider whether to initiate ICS treatment is based on a patient’s previous exacerbation history, and the blood eosinophil count (Fig. 5).08,09,99–102 Adding ICS has little or no effect at a blood eosinophil count <100 cells/µL whilst blood eosinophils ≥300 cells/µL identify patients with a strong likelihood of treatment benefit.103,104 There is a continuous gradation of the preventive effect of ICS in patients with eosinophil values between 100 and 300 cells/µL, so some patients are likely to get benefit from adding ICS.103,104 Treatment decisions can be based on historical eosinophil counts as the repeatability of blood eosinophil counts in a large primary care population appears reasonable,105 although greater variability is observed at higher thresholds.106

Chronic Bronchitis

Chronic Bronchitis (CB) has been traditionally defined by “cough and sputum production for at least 3 months per year for two
**Follow-up Pharmacological Treatment**

1. **If response to initial treatment is appropriate, maintain it.**
   - Check adherence, inhaler technique and possible interfering comorbidities
   - Consider the predominant treatable trait to target (dyspnea or exacerbations)
     - Use exacerbation pathway if both exacerbations and dyspnea need to be targeted
   - Place patient in box corresponding to current treatment & follow indications
   - Assess response, adjust and review
   - These recommendations do not depend on the ABE assessment at diagnosis

2. **If not:**
   - Consider switching inhaler device or molecules
   - Implement or escalate non-pharmacologic treatment(s)
   - Investigate (and treat) other causes of dyspnea

**Dyspnea**

- LABA or LAMA
- LABA + LAMA

**Exacerbations**

- LABA or LAMA
- LABA + LAMA
- LABA + LAMA + ICS

*Single inhaler therapy may be more convenient and effective than multiple inhalers*

**Consider de-escalation of ICS if pneumonia or other considerable side-effects. In case of blood eos ≥ 300 cells/µl de-escalation is more likely to be associated with the development of exacerbations. Exacerbation history refers to exacerbations suffered the previous year. mMRC: modified Medical Research Dyspnea Questionnaire. CAT: COPD Assessment Test. LAMA: long-acting anti-muscarinic antagonist; LABA: long-acting β2 receptor agonist; ICS: inhaled corticosteroid; eos: eosinophils. Reproduced with permission from www.goldcopd.org.

**Fig. 4.** Follow-up pharmacological treatment. *: single inhaler therapy may be more convenient and effective than multiple inhalers; **: consider de-escalation of ICS if pneumonia or other considerable side-effects. In case of blood eos ≥ 300 cells/µl de-escalation is more likely to be associated with the development of exacerbations. Exacerbation history refers to exacerbations suffered the previous year. mMRC: modified Medical Research Dyspnea Questionnaire. CAT: COPD Assessment Test. LAMA: long-acting anti-muscarinic antagonist; LABA: long-acting β2 receptor agonist; ICS: inhaled corticosteroid; eos: eosinophils. Reproduced with permission from www.goldcopd.org.

consecutive years” (in the absence of another cause that can explain this, a caveat that is often forgotten). The prevalence of CB in COPD patients ranges from 27 to 35%, being higher in males, younger age, greater pack-years of smoking, more severe airflow obstruction, rural location and increased occupational exposures. CB is associated with accelerated lung function decline, exacerbations, and mortality in COPD patients. Treatment of CB is unresolved but can include smoking cessation, long-acting muscarinic antagonists, oral mucolytics and antioxidants or oscillating positive expiratory pressure therapy; the use of inhaled mucolytics or recombinant human DNase have not shown promise. Liquid nitrogen metered cryospray, rheoplasty, and targeted lung denervation are currently undergoing evaluation for CB treatment.

**Affordability of Inhaled Medicines**

In LMICs, there is limited availability and affordability of essential inhaled therapies for people with COPD, and this global inequity must be addressed urgently as part of efforts to achieve Universal Health Coverage and Sustainable Development Goal 3. On the other hand, even in developed countries, most inhaled medicines are still branded.

**Reducing Lung Function Decline and Mortality in COPD**

Pharmacotherapy has the potential to reduce the rate of lung function decline, but further studies are needed to know what patients can benefit most since not all patients exhibit accelerated lung function decline. On the other hand, a number of pharmacologic and non-pharmacologic interventions (Fig. 6) reduce mortality in selected COPD patients. This emphasizes the need to implement targeted case-finding strategies, apply adequate patient characterization and provide appropriately individualized therapy.

**Non-pharmacological Therapy**

Non-pharmacological treatment is a key part of the comprehensive management of COPD.

**Education**

All patients should receive basic information about COPD and its treatment (respiratory medications and inhalation devices), strategies to minimize dyspnea, and advice about when to seek help.

**Smoking Cessation**

Approximately 40% of people with COPD continue to smoke despite knowing they have the disease, and this behavior has a negative impact on prognosis and progression of the disease. All patients who continue to smoke should be offered help and treatment to quit.
### Factors to Consider when Initiating ICS Treatment

**Factors to consider when adding ICS to long-acting bronchodilators:**  
(note the scenario is different when considering ICS withdrawal)

<table>
<thead>
<tr>
<th>STRONGLY FAVORS USE</th>
<th>FAVORS USE</th>
<th>AGAINST USE</th>
</tr>
</thead>
<tbody>
<tr>
<td>History of hospitalization(s) for exacerbations of COPD*</td>
<td>1 moderate exacerbation of COPD per year</td>
<td>Repeated pneumonia events</td>
</tr>
<tr>
<td>≥ 2 moderate exacerbations of COPD per year*</td>
<td>Blood eosinophils 100 to &lt; 300 cells/µL</td>
<td>Blood eosinophils &lt; 100 cells/µL</td>
</tr>
<tr>
<td>Blood eosinophils ≥ 300 cells/µL</td>
<td>History of, or concomitant asthma</td>
<td>History of mycobacterial infection</td>
</tr>
</tbody>
</table>

*except appropriate long-acting bronchodilator maintenance therapy (see Figure 4 and GOLD report Table 3.4 for recommendations). *note that blood eosinophils should be seen as a continuum; quoted values represent approximate cut-points; eosinophil counts are likely to fluctuate.

Adapted from & reproduced with permission of the © ERS 2019: European Respiratory Journal 52 (6) 1803219; DOI: 10.1183/13993003.01219-2018 Published 13 December 2018

---

**Vaccination**

Depending on local guidelines, patients should be offered vaccination against influenza, pneumococcus, COVID-19, pertussis, herpes zoster, if they have not already received these.

**Physical Activity**

Physical activity is decreased in COPD patients so all COPD patients should be encouraged to keep active. The challenge is promoting and maintaining physical activity. Technology-based interventions have the potential to provide convenient and accessible means to enhance exercise self-efficacy, and to educate and motivate patients to make healthy lifestyle changes.

**Pulmonary Rehabilitation**

Pulmonary Rehabilitation (PR), including community and home-based, is beneficial. Accordingly, patients with high symptom burden and risk of exacerbations (GOLD groups B and E) should be recommended to take part in a formal PR program designed and delivered in a structured manner, considering the individual's COPD characteristics and comorbidities.

Tele-rehabilitation has been proposed as an alternative to the traditional approaches. This has become even more relevant in the COVID-19 pandemic era where in-person PR has not been feasible. However, it is important to distinguish between evidence-based tele-rehabilitation models and pandemic-adapted models. Multiple trials performed in groups and individuals with a large variety of tele-rehabilitation delivery platforms (videoconferencing, telephone only, website with telephone support, mobile application with feedback, centralized “hub” for people to come together) suggest that telerehabilitation is safe and has similar benefits to those of center-based PR across a range of outcomes. However, the optimal form of delivery, content and duration are not yet established.

**Oxygen Therapy & Ventilatory Support**

The criteria for prescribing long term oxygen therapy and ventilator support remain unchanged and are described in detail in the GOLD 2023 report.

**Surgical and Endoscopic Lung Volume Reduction**

In selected patients with symptomatic heterogeneous or homogenous emphysema and significant hyperinflation refractory to optimized medical care, surgical or bronchoscopic modes of lung volume reduction may be considered (Fig. 7). In patients with a large bulla, surgical bullectomy is an option, and in selected patients with very severe COPD and without relevant contraindications, lung transplantation may be considered.

**End of Life and Palliative Care**

All patients with advanced COPD should be considered for end of life and palliative care support to optimize symptom control and allow patients and their families to make informed choices about future management.
**Fig. 6.** Evidence supporting a reduction in mortality with pharmacotherapy and non-pharmacotherapy in COPD patients. *: RCT with pre-specified analysis of the mortality outcome (primary or secondary outcome). #: Not conclusive results likely due to differences in PR across a wide range of participants and settings. Definition of abbreviations: ICS: inhaled corticosteroids; LABA: long-acting β2-agonist; LAMA: long-acting anti-muscarinic. Reference correspondence: 1. 89,192; 2. 193; 3. 156,157,194; 4.155,196; 5,197; 6. 198.
Reproduced with permission from www.goldcopd.org.

### Exacerbations of COPD

#### A New Definition

Exacerbations of COPD (ECOPD) negatively impact health status, disease progression and prognosis. The previous GOLD definition of ECOPD was highly non-specific ("acute worsening of respiratory symptoms that result in additional therapy").

Besides, the severity of ECOPD was determined post facto (mild, moderate or severe) based on the use of healthcare resources, which is useless to guide treatment at the point of care.

To address these limitations, GOLD 2023 has adopted the recent consensus Rome proposal which defines ECOPD as: "an event characterized by dyspnea and/or cough and sputum that worsen over ≤14 days, which may be accompanied by tachypnea and/or tachycardia and is often associated with increased local and systemic inflammation caused by airway infection, pollution, or other insult to the airways".

### Differential Diagnosis

Patients with COPD are at increased risk of other acute events, particularly decompensated heart failure, pneumonia and/or pulmonary embolism that may mimic or aggravate an ECOPD

(Fig. 8). Thus, while worsening of dyspnea, particularly if associated with cough and, purulent sputum, and no other symptoms or signs in a patient with COPD may be diagnosed as an ECOPD, other patients may have worsening of respiratory symptoms, particularly dyspnea without the classic characteristics of ECOPD, that should prompt careful consideration and/or search of those potential confounders, or contributors.

### Assessment of ECOPD Severity

Based on a thorough review of the available literature and using a Delphi approach to agree on the variable thresholds, the Rome proposal suggests using easy to obtain clinical variables to define the severity of ECOPD (mild, moderate or severe) at the point of care (Fig. 8). In the primary care setting, severity can be determined with the easily obtainable dyspnea intensity (using a VAS 0–10 dyspnea scale with zero being not short of breath at all and 10 the worst shortness of breath you have ever experienced), respiratory rate, heart rate and oxygen saturation level. Where available, measuring blood C-reactive protein (CRP) levels is recommended (Fig. 8). To determine the need for ventilatory support (usually in the emergency room or hospital setting) arterial blood gases should be measured. To move from a mild to a moderate level, three of the variables need to exceed the established thresholds.

---

**Table 6:** Evidence Supporting a Reduction in Mortality with Pharmacotherapy and Non-pharmacotherapy in COPD Patients

<table>
<thead>
<tr>
<th>Therapy</th>
<th>RCT*</th>
<th>Treatment effect on mortality</th>
<th>Patient characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pharmacotherapy</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LABA+LAMA+ICS</td>
<td>Yes</td>
<td>Single inhaler triple therapy compared to dual LABD therapy relative risk reduction: IMPACT: HR 0.72 (95% CI: 0.53, 0.99)(^{13})</td>
<td>Symptomatic people with a history of frequent and/or severe exacerbations</td>
</tr>
<tr>
<td><strong>Non-pharmacological Therapy</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoking cessation(^{1})</td>
<td>Yes</td>
<td>HR for usual care group compared to intervention group (smoking cessation) HR 1.18 (95% CI: 1.02, 1.37)(^{7})</td>
<td>Asymptomatic or mildly symptomatic</td>
</tr>
<tr>
<td>Pulmonary rehabilitation(^{1})</td>
<td>Yes</td>
<td>Old trials: RR 0.28 (95% CI 0.10, 0.84)(^{14}) New trials: RR 0.68 (95% CI 0.28, 1.67)(^{18})</td>
<td>Hospitalized for exacerbations of COPD (during or ≤ 4 weeks after discharge)</td>
</tr>
<tr>
<td>Long-term oxygen therapy(^{4})</td>
<td>Yes</td>
<td>NOTT: ≥ 19 hours of continuous oxygen vs ≤ 13 hours: 50% reduction(^{19}) MRC: ≥ 15 hours vs no oxygen: 50% reduction(^{20})</td>
<td>PaO(_2) ≤ 55 mmHg or &lt; 60 mmHg with cor pulmonale or secondary polycythemia</td>
</tr>
<tr>
<td>Noninvasive positive pressure ventilation(^{4})</td>
<td>Yes</td>
<td>12% in NPPV (high IPAP level) and 33% in control</td>
<td>Stable COPD with marked hypercapnia</td>
</tr>
<tr>
<td>Lung volume reduction surgery(^{4})</td>
<td>Yes</td>
<td>0.07 deaths/person-year (LURS) vs 0.15 deaths/person-year (UC) RR for death 0.47 (p = 0.005)(^{6})</td>
<td>Upper lobe emphysema and low exercise capacity</td>
</tr>
</tbody>
</table>

\*RCT with pre-specified analysis of the mortality outcome (primary or secondary outcome). ^Inconclusive results likely due to differences in pulmonary rehabilitation across a wide range of participants and settings.

1. a) IMPACT trial (Lassen et al. 2020) and b) ETHOS trials (Martínez et al. 2021); 2. Lung Health Study (Anthonisen et al. 2005); 3. a) Puhan et al. (2013) and b) Puhun et al. 2016; 4. a) NOTT (NOTT, 1990) and b) MRC (MRC, 1991); 5. Kohlein trial (Kohlein et al. 2014); 6. NETT trial (Fishman et al. 2003)

ICS: inhaled corticosteroid; IPAP: Inspiratory positive airway pressure; LABA: long-acting β2-agonist; LAMA: long-acting anti-muscarinic; RCT: randomized controlled trial; IMPACT: Inhaled Nebulized Budesonide and Formoterol; IMPACT: Inhaled Nebulized Budesonide; ETHOS: Efficacy Trials for Hospitalized Severe Acute COPD Exacerbations; MRC: Medical Research Council; PaO\(_2\): Arterial oxygen partial pressure; NPPV: Noninvasive Positive Pressure Ventilation; LURS: Lung Volume Reduction Surgery; UC: usual treatment control group.
It is hoped that prospective validation will help better define exacerbations and their severity at point of contact, and that documented validation may confirm or help modify the proposed thresholds of the variables now included. Likewise, it is proposed that prospective research can help determine a more specific marker of lung injury than the more generic CRP, as has been true for acute events of other organs (e.g., troponin level in patients with acute myocardial infarction).

Management of ECOPD

Treatment Setting

Depending on the episode severity, as well as that of the underlying COPD and comorbidities, an ECOPD can be managed in either the outpatient or inpatient setting. The following are indications for hospitalization: (1) severe symptoms such as sudden worsening of resting dyspnea, high respiratory rate, decreased oxygen saturation, confusion, drowsiness; (2) acute respiratory failure; (3) onset of new physical signs (e.g., cyanosis, peripheral edema); (4) failure to respond to initial medical management; (5) presence of serious comorbidities (e.g., heart failure, newly occurring arrhythmias, etc.); and, (6) insufficient home support.

In the emergency department, hypoxemic patients should be provided with the appropriate concentration of supplemental oxygen and be assessed to determine if the increased work of breathing or impaired gas exchange require non-invasive ventilation. If so, healthcare providers should consider admission to an area where proper monitoring and care can be provided. In less severe cases, the patient may be managed in the emergency department or hospital ward unit.

Pharmacological Treatment

Bronchodilators. Short-acting inhaled β2-agonists (SABA), with or without short-acting anticholinergics (SAMA), are the initial bronchodilators for acute treatment of ECOPD, administered using a metered-dose inhaler (MDI, with a spacer device if necessary, or nebulization). If a nebulizer is chosen, air-driven is preferable to oxygen-driven nebulization to avoid the potential risk of increasing PaCO₂. The GOLD 2023 report recommends continuing treatments with long-acting bronchodilators during the exacerbation or to start these medications as soon as possible before hospital discharge. Intravenous methylxanthines (theophylline or aminophylline) are not recommended due to lack of efficacy and significant side effects.

Glucocorticoids. Systemic glucocorticoids in COPD exacerbations improve lung function, oxygenation, risk of early relapse, and reduce treatment failures and length of hospitalization. A dose of 40 mg prednisone-equivalent per day for 5 days is recommended. Longer courses increase risk of pneumonia and mortality. Therapy with oral prednisolone is equally effective to intravenous administration. Nebulized budesonide may be a suitable alternative to systemic corticosteroids in some patients. Recent studies suggest that glucocorticoids may be less efficacious to treat COPD exacerbations in patients with lower blood eosinophil levels.

Antibiotics. Antibiotics should be given to patients with ECOPD who have increased sputum volume and sputum purulence and most of those requiring mechanical ventilation (invasive or noninvasive). The recommended length of antibiotic therapy is...
Fig. 8. Classification of the severity of COPD exacerbations. Definition of abbreviations: VAS: visual analog scale; RR: respiratory rate; HR: heart rate; CRP: C-reactive protein. SaO$_2$: arterial oxygen saturation; PaO$_2$: arterial partial pressure of oxygen; ABG: arterial blood gases; ABG should show new onset/worsening hypercapnia or acidosis since a few patients may have chronic hypercapnia. Adapted from Ref. 120. Reproduced with permission from www.goldcopd.org.
5–7 days.\textsuperscript{135} The choice of the antibiotic should be based on the local bacterial resistance pattern. Usually, initial empirical treatment is an aminopenicillin with clavulanic acid, macrolide, tetracycline or, in selected patients, quinolone. In patients with frequent exacerbations, severe airflow obstruction and/or exacerbations requiring mechanical ventilation, cultures from sputum or other materials from the lung should be performed, as gram-negative bacteria (e.g., \textit{Pseudomonas} species) or resistant pathogens that are not sensitive to the above-mentioned antibiotics may be present. The route of administration (oral or intravenous) depends on the patient’s ability to ingest medications and the pharmacokinetics of the antibiotic.

\textit{Adjunct Therapies}. Additional therapies may be indicated to maintain appropriate fluid balance, treat the comorbidities and monitor nutritional aspects. Hospitalized patients with COPD are at an increased risk of deep vein thrombosis and pulmonary embolism and prophylactic measures for thromboembolism should be instituted.\textsuperscript{136,137} At all times, healthcare providers should strongly enforce the need for smoking cessation.

\textit{Oxygen Therapy}. Supplemental oxygen for hypoxemia should be titrated to a target saturation of 88–92%.\textsuperscript{1,14} In severe COPD, blood gases should be checked frequently or as clinically indicated to monitor for carbon dioxide retention and/or worsening acidosis. Pulse oximetry is not as accurate as arterial blood gas measurement\textsuperscript{139} and, in particular, may overestimate blood oxygen content among individuals with darker skin tones.\textsuperscript{140} Venturi masks offer more accurate and controlled delivery of inspired oxygen than do nasal prongs.\textsuperscript{1}

High-flow nasal therapy (HFNT) delivers heated and humidified air-oxygen blends via special devices at rates up to 8 L/min in infants and up to 60 L/min in adults.\textsuperscript{141} HFNT has been associated with decreased respiratory rate and effort, improved lung mechanics and gas exchange, prolonged time to next exacerbation and improved health-related quality of life scores in COPD patients with acute (or chronic) hypercapnia,\textsuperscript{142–144} but did not prevent intubation in hospitalized patients with ECOPD.\textsuperscript{145} In fact, the European Respiratory Society (ERS) recommends ventilatory support before using HFNT in hypercapnic ECOPD.\textsuperscript{146}

\textit{Ventilatory Support}. Ventilatory support can be provided by either noninvasive (NIV) means, with a nasal or facial mask, or invasive means, with an oro–tracheal tube or trachoeotomy vent. NIV is the preferred initial mode of ventilation.\textsuperscript{147,148} It improves gas exchange and decreases respiratory rate, work of breathing, severity of breathlessness, intubation rates, complications (e.g., ventilator associated pneumonia), length of hospital stay and mortality.\textsuperscript{147,148} Once patients improve and can tolerate at least 4 h of unassisted breathing, NIV can be directly discontinued without any need for a “weaning” period.\textsuperscript{149}

Patients who fail non-invasive ventilation should receive invasive ventilation as subsequent rescue therapy.\textsuperscript{150} The use of invasive ventilation in COPD is influenced by the likely reversibility of the precipitating event, the patient’s wishes, and the availability of intensive care facilities.\textsuperscript{150} When possible advance directives or “living will”, makes these difficult decisions easier to resolve. Major hazards include the risk of ventilator-acquired pneumonia, barotrauma and volutrauma, and the risk of tracheostomy and consequential prolonged ventilation. Respiratory stimulants (e.g., caffeine, doxapram) are not recommended to treat ECOPD.\textsuperscript{1}

\textit{Hospital Discharge, Early Readmissions, and Follow-up}

There are no standards to the timing and nature of hospital discharge but early readmissions during the first 90 days after discharge are frequent and constitute a significant health care problem. A systematic review has shown that comorbidities, previous exacerbations and hospitalization, and increased length of stay were significant risk factors for 30- and 90-day all-cause readmission after a hospitalized COPD exacerbation.\textsuperscript{151} Hence, after an exacerbation it is good practice to cover education on correct use of the medications, provide support at home and a follow-up plan before discharge.\textsuperscript{152} Early follow-up (within one month) should also be scheduled as it has been related to less exacerbation-related readmissions.\textsuperscript{153} Additional follow-up at three months is recommended to ensure return to a stable clinical state and permit a review of the patient’s symptoms, lung function, and where possible the assessment of prognosis using multiple scoring systems such as the BOSE.\textsuperscript{154} In addition, arterial oxygen saturation and arterial blood gas assessment will determine the need for long-term oxygen therapy more accurately.\textsuperscript{155} The effects of initiation of pulmonary rehabilitation in the first 4 weeks post hospital discharge are unclear.\textsuperscript{156,157}

\textit{Prognosis}

Long-term prognosis following hospitalization for COPD exacerbation is poor, with a five-year mortality rate of about 50%.\textsuperscript{158} Factors independently associated with poor outcome include older age, lower BMI, comorbidities (e.g., cardiovascular disease or lung cancer), previous hospitalizations for COPD exacerbations, clinical severity of the index exacerbation and need for long-term oxygen therapy at discharge.\textsuperscript{159–161}

\textit{Comorbidities, Multimorbidity and Frailty}

COPD almost invariably coexists with other diseases (see below) that may significantly impact the patient’s clinical condition and prognosis.\textsuperscript{162} These comorbid conditions complicate the clinical picture because they can mimic the clinical presentation of COPD with similar complaints of dyspnea and chest tightness/pain and lead to misdiagnosis and missed opportunities for treatment. Additionally, comorbid conditions can further limit the pulmonary reserve of patients with COPD. Conversely, COPD may adversely affect the outcomes of many other disorders. For example, patients with heart failure or those undergoing coronary artery bypass grafting have greater morbidity and mortality when COPD is present compared to when it is absent. Some comorbidities arise independently of COPD, but others are causally related, either by shared risk factors or by one disease compounding the severity of the other.\textsuperscript{163}

In general, the presence of comorbidities should not alter COPD treatment and comorbidities should be treated per usual standards regardless of the presence of COPD. Attention should be directed to ensure simplicity of treatment and to minimize polypharmacy.

\textit{Cardiovascular diseases}

Cardiovascular diseases are common in COPD, their prevalence ranging from 20 to 70%.\textsuperscript{164} The types of cardiovascular comorbid conditions are diverse and span the spectrum from congestive heart failure to ischemic heart disease, arrhythmias, peripheral vascular disease and hypertension.\textsuperscript{164} All these conditions should be treated in patients per established guidelines independent of the COPD diagnosis, including the use of selective \textit{β1}-blockers when a clear cardiovascular indication is present.

\textit{Lung cancer}

Lung cancer occurs frequently in patients with COPD.\textsuperscript{165} Like the general population, annual low-dose CT scan is recommended for lung cancer screening in COPD due to smoking.\textsuperscript{78,79} In patients
with COPD not due to smoking, there is insufficient data to establish benefit over harm from lung cancer screening.

Bronchiectasis

Bronchiectasis affects approximately 30% of patients with COPD. Increased sputum production, recurrent infections, and more frequent exacerbations hallmark bronchiectasis when it accompanies COPD. A chest CT scan is recommended if bronchiectasis is suspected.

Sleep apnea

Sleep apnea occurs in approximately 14% of COPD patients. This worsens their prognosis since they have more frequent episodes of oxygen desaturation and a longer sleep time with hypoxemia and hypercapnia than OSA patients without COPD.

Osteoporosis

Osteoporosis in COPD is often under-diagnosed and associated with poor health status and prognosis. Recurrent use of systemic corticosteroids increases the risk of osteoporosis and should be avoided if possible.

Diabetes and Metabolic Syndrome

Studies show that diabetes is more frequent in COPD and the latter is likely to affect prognosis. The prevalence of metabolic syndrome has been estimated to be more than 30%. Diabetes and metabolic syndrome should be treated according to usual guidelines. COPD should be treated as usual.

Gastroesophageal Reflux (GERD)

GERD is an independent risk factor for exacerbations and is associated with worse health status. The mechanisms responsible for increased risk of exacerbations are not yet fully established. Proton pump inhibitors are often used for treatment of GERD. One small, single-blind study suggested that these agents decrease the risk of exacerbation, but their value in preventing these events remains controversial, and the most effective treatment for this condition in COPD has yet to be established.

Anemia

Anemia is frequent in patients with COPD. These patients are generally older, have more frequent cardiometabolic comorbidities, greater dyspnea, worse quality of life and airflow obstruction, reduced exercise capacity, and an increased risk of severe exacerbations with a higher mortality.

Secondary polycythemia

Secondary polycythemia may be associated with pulmonary hypertension and venous thromboembolism and mortality. Although the prevalence of polycythemia in COPD has decreased following the introduction of long-term oxygen therapy (LTOT), one study reported its presence in 8.4% of patients with severe COPD receiving LTOT.

Mental Health

Anxiety and depression are important and underdiagnosed comorbidities in COPD. Both are associated with poor prognosis, younger age, female sex, smoking, lower FEV1, cough, higher SGRQ score, and a previous history of cardiovascular disease. Cognitive impairment occurs in 32% of people with COPD, but neuropsychological testing suggests that up to 56% of them may suffer from it.

Multimorbidity and Frailty

An increasing number of aging patients suffer multi-morbidity, defined as the presence of two or more chronic conditions. These patients have symptoms from multiple diseases making their presentation complex in the acute or chronic state. Multimorbidity results in frailty hallmarking by the presence of weakness, fatigue, exhaustion, low physical activity, and unintentional weight loss, a condition that has been reported to be more prevalent in patients with COPD.

COPD and COVID-19

Patients should follow basic infection control measures to help prevent SARS-CoV-2 infection including social distancing and washing hands which are associated with reductions in the incidence COVID-19. They should have COVID-19 vaccination in line with national guidelines. At times of high community incidence of COVID-19, patients should be advised to wear a facial covering and should keep taking their oral and inhaled respiratory medications for COPD as directed as there is no evidence that COPD medications should be changed during this COVID-19 pandemic.

Marked reductions in exacerbation rates and hospitalization for COPD have been reported during the initial phases of the pandemic, possibly because of infection control measures. Physical distancing and shielding, or sheltering-in-place, should not lead to social isolation and inactivity. Patients should stay in contact with their friends and families by telecommunication and continue to keep active. They should also ensure they have enough medication.

COPD patients are not at increased risk of infection with SARS-CoV-2, but this may reflect the effect of protective strategies. After accounting for potential confounding variables, COPD patients do have a higher risk of hospitalization, ICU admission, and mortality. COPD patients presenting with new or worsening respiratory or other symptoms that could be COVID-19 related, even if these are mild, should be tested for SARS-CoV-2.

New Opportunities

COPD is a common, preventable, and treatable disease, but extensive under-diagnosis and misdiagnosis leads to patients receiving no treatment or incorrect treatment. The realization that environmental factors other than tobacco smoking can contribute to COPD, that it can start early in life and affect young individuals, and that there are precursor conditions (“Pre-COPD”, “PRISm”), opens new windows of opportunity for its prevention, early diagnosis, and prompt and appropriate therapeutic intervention. Importantly, several pharmacological and non-pharmacological therapies have now been shown to reduce mortality of COPD patients but, in order to implement them, COPD must be diagnosed. Thus, any strategy aimed at addressing and improving the huge underdiagnosis of COPD in the community should be reinforced.

Conflict of interests

Author disclosures are available at www.goldcopd.org
Acknowledgments
Authors acknowledge the support of Katie Langefeld and Ruth Hadfield for their careful editing of this 2023 GOLD report, as well as that of the members of the GOLD Emerti Academy, GOLD Assembly and industry stakeholders for their comments and feed-back.

Appendix A. Supplementary data
Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.jarbres.2023.02.009.

References


